Lynparza 150 mg/1

Lynparza 150 mg is a medication used in cancer treatment. It contains olaparib, a PARP inhibitor, and is available in film-coated tablet form. This drug is commonly prescribed for specific types of cancer, including ovarian and breast cancer.

Lynparza 150 mg is primarily used in the treatment of certain types of cancer. It is often prescribed for patients with ovarian cancer who have a specific genetic mutation. Additionally, it may be used in the treatment of breast cancer in patients with a BRCA mutation. The medication works by targeting and inhibiting an enzyme involved in DNA repair, which can help slow the growth of cancer cells.

Common effects of Lynparza 150 mg may include fatigue, nausea, and vomiting. Some patients may also experience anemia, which can cause weakness and shortness of breath. It is important to discuss any side effects with a healthcare provider to ensure proper management.

Lynparza 150 mg should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions.

Lynparza 150 mg may interact with certain medications, including those that affect liver enzymes. It is important to discuss all current medications with a healthcare provider before starting Lynparza. Additionally, alcohol and other substances may affect the efficacy of the medication.